Biotech Values

[maverick_1]

Ph1 Duke's GBM Polio Vaccine featured on CBS since 2015:

https://medschool.duke.edu/about-us/news-and-communications/med-school-blog/immunotherapy-glioblastoma-well-tolerated-survival-gains-observed

VS

Ph3 DCVAX L ending soon with 331 patients in 51 locations as intimated via:

1)STAT NEWS:

Manufacturer Northwest Biotherapeutics has recruited 331 glioblastoma patients into a late-stage clinical trial, and at this year’s meeting of the American Society of Clinical Oncology reported that:
1) 40 percent of patients treated with “DCVax-L” were still alive at 35 months, compared with 15 percent of patients receiving standard care;
2)24 percent of patients who got the vaccine were alive after four years. compared with 8 percent otherwise/quote]
(The median survival time for people with glioblastoma is 14.6 months.)
https://www.statnews.com/2017/07/21/mccain-glioblastoma-treatments/

2)Fox News:

https://video.foxnews.com/v/5513640393001/?#sp=show-clips

https://clinicaltrials.gov/ct2/show/study/NCT00045968?show_locs=Y#locn

DIFFERENT STROKES FOR DIFFERENT FOLKS